Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF THE REMUNERATION AND APPRAISAL COMMITTEE AND THE NOMINATION COMMITTEE APPOINTMENT OF EMPLOYEE REPRESENTATIVE DIRECTOR ABOLISHMENT OF THE BOARD OF SUPERVISORS

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (the "**Company**" and its subsidiaries, the "**Group**") pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Reference is made to the announcement (the "**Previous Announcement**") and circular (the "**Circular**") of the Company, both dated 5 September 2025, and the supplemental circular (the "**Supplemental Circular**") of the Company dated 15 September 2025 in relation to, among other things, the proposed election of Dr. Yang Jin as an Independent Non-executive Director and the proposed abolishment of the Board of Supervisors.

Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Previous Announcement, Circular and Supplemental Circular.

I. ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") is pleased to announce that resolution number 1 regarding the election of Dr. Yang Jin as an Independent Non-executive Director was approved at the EGM held on 29 September 2025. The election of Dr. Yang Jin as an Independent Non-executive Director has become effective on the date of the EGM, being 29 September 2025. Poll results of the EGM are set out in the poll results announcement of the Company dated 29 September 2025.

The biographical details and other relevant information regarding Dr. Yang Jin are set out in the Previous Announcement and the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company will enter into a service contract with Dr. Yang Jin in relation to his election as an Independent Non-executive Director for a term commencing from the date of approval of his election at the EGM, being 29 September 2025, and expiring on the conclusion of the fourth session of the Board. This term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Hong Kong Listing Rules. Under the terms of the service contract, the director's fee payable to Dr. Yang Jin will be RMB200,000 per annum, which was determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Dr. Yang Jin has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Hong Kong Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Dr. Yang Jin has confirmed that (i) he has satisfied all the standards for independence as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or connection with any core connected person (as defined in the Hong Kong Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there are no other matters concerning Dr. Yang Jin's election as an Independent Non-executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

The Board would like to take this opportunity to extend a warm welcome to Dr. Yang Jin for joining the Board.

II. CHANGE IN COMPOSITION OF THE REMUNERATION AND APPRAISAL COMMITTEE AND THE NOMINATION COMMITTEE

The Board is pleased to announce that, following the resolution regarding the election of Dr. Yang Jin as an Independent Non-executive Director being passed at the EGM, with effect from 29 September 2025, Dr. Yang Jin is elected as a member of the Remuneration and Appraisal Committee, and Ms. Lu Kun is elected as a member of the Nomination Committee. Both terms shall commence from the approval date of the EGM, being 29 September 2025, until the end of term of the fourth session of the Board. Following the above changes, the composition of the Remuneration and Appraisal Committee and the Nomination Committee will be as follows:

(i) the Remuneration and Appraisal Committee comprises three Independent Non-executive Directors, namely Mr. Zhang Chun (chairman of the Remuneration and Appraisal Committee), Dr. Feng Xiaoyuan and Dr. Yang Jin, and two executive Directors, namely Mr. Xiong Jun and Dr. Zou Jianjun; and

(ii) the Nomination Committee comprises two Independent Non-executive Directors, namely Dr. Feng Xiaoyuan (chairman of the Nomination Committee) and Ms. Lu Kun, and one executive Director, namely Mr. Xiong Jun.

The Board would like to take this opportunity to extend a warm welcome to Dr. Yang Jin and Ms. Lu Kun for taking up new positions.

III. APPOINTMENT OF EMPLOYEE REPRESENTATIVE DIRECTOR

At the Company's employee representatives meeting held on 26 September 2025 (the "**Employee Representatives Meeting**"), the employee representatives resolved to appoint Dr. Li Xin ("**Dr. Li**") as an employee representative director of the fourth session of the Board.

Resolution number 3 regarding, among others, the amendments to the Articles of Association and its appendices, was approved at the EGM held on 29 September 2025. The requirement of electing an employee representative director has become effective on the date of the EGM, being 29 September 2025. Dr. Li is elected as an employee representative director, and continues to be an executive director of the fourth session of the Board until the end of term of the fourth session of the Board.

The biography of Dr. Li is as follows:

Dr. Li, aged 46, joined the Group in October 2023. She obtained a Ph.D degree in Enterprise Development and Strategic Management from Fudan University in 2005 and obtained an Executive Master of Business Administration (EMBA) degree from the Tsinghua University PBC School of Finance. She has been serving as an executive Director and the Senior Vice President of Government Affairs of the Company since February 2024, and served as a non-executive Director from October 2023 to February 2024. From September 2014 to December 2020, she served as the vice president of Greenland Financial Holdings Group Co., Ltd.* (綠地金融投資控股集團有限公司). She served as the vice president of Greenland Jinchuang Technology Group Co., Ltd.* (綠地金創科技集團有限公司) from January 2021 to August 2024; a director of Greenland Digital Technology Co., Ltd.* (綠地數字科技有限公司) since August 2022; and an executive director of Shanghai Jiacai Investment Management Co., Ltd.* (上海加財投資管理有限公司) since April 2015.

IV. ABOLISHMENT OF THE BOARD OF SUPERVISORS

The Board announces that, as the proposed amendments to the Articles of Association set out in the Circular include the abolishment of the Board of Supervisors, and accordingly, upon approval of the amendments to the Articles of Association by the Shareholders at the EGM held on 29 September 2025, the Company ceases to have the Board of Supervisors.

The Board would like to express its sincere appreciation to all supervisors for their valuable contributions to the Company during their tenure of office.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 29 September 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as Independent Non-executive Directors.

* *For identification purpose only*